<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03610880</url>
  </required_header>
  <id_info>
    <org_study_id>TGDAG-C-1</org_study_id>
    <nct_id>NCT03610880</nct_id>
  </id_info>
  <brief_title>To Evaluate PK and Safety Profile of Oral MAD of Separately Using TG-2349, DAG181 or Combination in Healthy Chinese Volunteers</brief_title>
  <official_title>A Single Center, Randomized, Open-label, Two-arm, Parallel Design Study to Evaluate PK and Safety Profile of Multiple Ascending Oral Doses of Separately Using TG-2349 or DAG181 or TG-2349 Plus DAG181 in Healthy Chinese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>R&amp;G Pharma Studies Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the drug-drug reactions between TG-2349 and DAG181, and the pharmacokinetics and&#xD;
      tolerability profile in healthy Chinese volunteers to be the reference for protocol designs&#xD;
      of subsequent clinical trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center, randomized, open-label, two-arm, parallel design, phase I study that&#xD;
      using TG-2349 or DAG181 alone, or TG-2349 plus DAG181 to evaluate the drug-drug reactions,&#xD;
      the pharmacokinetics, and tolerability profile in healthy Chinese volunteers. The results&#xD;
      will be the reference for protocol designs of subsequent clinical trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Actual">February 5, 2018</completion_date>
  <primary_completion_date type="Actual">February 5, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, open-label, two-arm, parallel design</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax(ss)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Maximum Plasma Concentration in a stable state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctrough(ss)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Trough Plasma Concentration in a stable state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-τ, ss)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Area Under the Plasma Concentration vs. Time Curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>14 weeks</time_frame>
    <description>Cmax: Maximum Plasma Concentration,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>14 weeks</time_frame>
    <description>Ctrough: Trough Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>14 weeks</time_frame>
    <description>Time at Which Maximum Plasma Concentration is Observed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24)</measure>
    <time_frame>14 weeks</time_frame>
    <description>AUC(0-24): Area Under the Plasma Concentration vs. Time Curve 0-24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax(ss)</measure>
    <time_frame>14 weeks</time_frame>
    <description>Tmax(ss): Time at Which Maximum Plasma Concentration is Observed in a stable state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz</measure>
    <time_frame>14 weeks</time_frame>
    <description>λz: Terminal disposition rate constant/terminal rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-last)</measure>
    <time_frame>14 weeks</time_frame>
    <description>AUC(0-last): Area Under the Plasma Concentration vs. Time Curve 0 - the last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-inf)</measure>
    <time_frame>14 weeks</time_frame>
    <description>AUC(0-inf): Area Under the Plasma Concentration vs. Time Curve 0 - infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT</measure>
    <time_frame>14 weeks</time_frame>
    <description>MRT: mean residence time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>14 weeks</time_frame>
    <description>CL/F: total clearance rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>V/F</measure>
    <time_frame>14 weeks</time_frame>
    <description>V/F: apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DF</measure>
    <time_frame>14 weeks</time_frame>
    <description>DF=(Cmax - Ctrough) / (AUCss /τ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>19 weeks</time_frame>
    <description>including heart rate, RR, PR, QRS, QT, QTc；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>19 weeks</time_frame>
    <description>CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure (mmHg)</measure>
    <time_frame>19 weeks</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse (beats/ min)</measure>
    <time_frame>19 weeks</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory rate (breaths/ min)</measure>
    <time_frame>19 weeks</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body temperature (oC)</measure>
    <time_frame>19 weeks</time_frame>
    <description>Vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Appearance Physical examination</measure>
    <time_frame>19 weeks</time_frame>
    <description>Physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Physical examination</measure>
    <time_frame>19 weeks</time_frame>
    <description>Physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head and Neck Physical examination</measure>
    <time_frame>19 weeks</time_frame>
    <description>Physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest region Physical examination</measure>
    <time_frame>19 weeks</time_frame>
    <description>Physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal region Physical examination</measure>
    <time_frame>19 weeks</time_frame>
    <description>Physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back region Physical examination</measure>
    <time_frame>19 weeks</time_frame>
    <description>Physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extremities Physical examination</measure>
    <time_frame>19 weeks</time_frame>
    <description>Physical examination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Chinese Volunteers</condition>
  <arm_group>
    <arm_group_label>TG-2349 (400 mg) plus DAG181 (200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing period 1 (Day 1 to 7): TG-2349 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DAG181 (200 mg) plus TG-2349 (400 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing period 1 (Day 1 to 7): DAG181 alone；Dosing period 2 (Day 8 to 14): TG-2349+DAG181</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TG-2349 (400 mg) plus DAG181 (200 mg)</intervention_name>
    <description>Dosing period 1 (Day 1 to 7): TG-2349 400 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg</description>
    <arm_group_label>TG-2349 (400 mg) plus DAG181 (200 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAG181 (200 mg) plus TG-2349 (400 mg)</intervention_name>
    <description>Dosing period 1 (Day 1 to 7): DAG181 200 mg； Dosing period 2 (Day 8 to 14): TG-2349 400 mg + DAG181 200 mg</description>
    <arm_group_label>DAG181 (200 mg) plus TG-2349 (400 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Before starting the study, an informed consent form (ICF) approved by the Institute&#xD;
             Review Board (IRB) is obtained from the subject or his/her legal representative；&#xD;
&#xD;
          2. Male or female, and 18 to 45 years of age inclusive when signing ICF；&#xD;
&#xD;
          3. Body mass index (BMI) in the range of 19.0 to 24.0 kg/m2 inclusive and male body&#xD;
             weight ≥ 50 kg, female body weight ≥ 45 kg；&#xD;
&#xD;
          4. In general good physical and mental health status on basis of medical history review,&#xD;
             physical examination and vital signs, 12-lead ECG, and laboratory results at&#xD;
             screening；&#xD;
&#xD;
          5. For females, one of the following criteria must be fulfilled: (a) Had undergone&#xD;
             surgical sterilization, or (b) Subjects of childbearing potential must satisfy the&#xD;
             following criteria: Before group assignment, the urine pregnancy test is negative, and&#xD;
             Subjects agree to use an approved contraceptive method (i.e. oral spermicidal agent,&#xD;
             condoms, or intrauterine devices) during the entire study period (from Visit1 to Visit&#xD;
             2). Subject must also consent to keep the contraceptive method until 1 month after the&#xD;
             study, and Breastfeeding is prohibited；&#xD;
&#xD;
          6. Male must be willing to use a reliable form of contraception (use of a condom or&#xD;
             spouses using any of the above standards) during the entire study period (from Visit1&#xD;
             to Visit 2) and within 1 month after the study；&#xD;
&#xD;
          7. Have not used tobacco or nicotine-containing products within 1 month period to first&#xD;
             dose of study drug；&#xD;
&#xD;
          8. Willing to abstain from caffeine- or xanthine-containing beverages, including coffee&#xD;
             and tea, chocolate, alcohol, grapefruit juice, and Seville oranges juice before 24 hr&#xD;
             and during the Stay-on Site period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current, prior history, or family history of any disease of sudden cardiac death,&#xD;
             myocardial ischemia, myocardial infarction, congestive heart failure, QT prolongation&#xD;
             syndrome, hypokalemia, myocarditis, exertional dyspnea, cerebrovascular injury, venous&#xD;
             thromboembolism；&#xD;
&#xD;
          2. Requires concomitant medication associated with increased QTc interval (i.e. Class I&#xD;
             or III antiarrhythmic agents, refer to appendix 1) or with cardiac insufficiency；&#xD;
&#xD;
          3. Any abnormality on 12-lead ECG: PR&gt;240 ms, PR&lt;110 ms, QRS&gt;110 ms, QTc&gt;450 ms, or&#xD;
             bradycardia ( heart rate &lt; 50 beats/min) at screening or the day -1；&#xD;
&#xD;
          4. Any clinical significant abnormality on 12-lead ECG (i.e. atrioventricular block, TdT,&#xD;
             other types of ventricular tachycardia, atrial fibrillation and ventricular flutter,&#xD;
             clinical significant abnormality on T wave changes or any abnormality on 12-lead ECG&#xD;
             that effects QTc intervals) at screening or the day -1；&#xD;
&#xD;
          5. Systolic pressure &gt;140 mmHg or &lt;90 mmHg, diastolic pressure &gt;90 mmHg, pulse &lt;50&#xD;
             beats/min or &gt;100 beats/min at screening or the day -1；筛选或研究第-1天时收缩压&gt;140 mmHg或&lt;90&#xD;
             mmHg、舒张压&gt;90 mmHg、脉搏&lt;50次/分或&gt;100次/分；&#xD;
&#xD;
          6. Any clinical significant abnormality on chest X-rays or abdominal ultrasound scan at&#xD;
             screening (or within 2 weeks of signing the ICF)；&#xD;
&#xD;
          7. Positive serological test for hepatitis A (IgM anti-HAV), hepatitis B (HbsAg),&#xD;
             hepatitis C (anti-HCV antibody), or syphilis at screening；&#xD;
&#xD;
          8. Pregnant or breastfeeding；&#xD;
&#xD;
          9. Any abnormal laboratory values (normal value ±10％) that are considered clinical&#xD;
             significant by the Investigator at screening or the day -1；&#xD;
&#xD;
         10. Positive breath alcohol test or urine drug screen at screening or the day -1；&#xD;
&#xD;
         11. Current or prior history of any disease of diabetes, cardiovascular, hepatic or renal&#xD;
             impairment；&#xD;
&#xD;
         12. Any dysphagia, malabsorption syndrome, or other gastrointestinal disturbances&#xD;
             affecting drug absorption；&#xD;
&#xD;
         13. Difficulty with blood collection and/or poor venous access for the purposes of&#xD;
             phlebotomy；&#xD;
&#xD;
         14. History of epileptic seizure, mental disorders affecting the subject's compliance with&#xD;
             the protocol, suicidal risk, or a history of alcohol or illicit drug abuse；&#xD;
&#xD;
         15. Currently has any disease that seriously affects the immune system, for instance,&#xD;
             human immunodeficiency virus (HIV) infection, hematological malignancy, solid cancer&#xD;
             or splenectomy；&#xD;
&#xD;
         16. Allergy, hypersensitivity or allergic reaction to TG-2349 or its excipients, DAG181 or&#xD;
             its excipients,or Sulfonamides；&#xD;
&#xD;
         17. History of surgery within 6 months prior to the first dose of study drug；&#xD;
&#xD;
         18. Received any hepatic enzyme inducers or hepatic enzyme inhibitors within 30 days prior&#xD;
             to the first dose of study drug through medical history questionnaire (refer to&#xD;
             appendix 2)；&#xD;
&#xD;
         19. Received any investigational drugs within 3 months prior to the first dose of study&#xD;
             drug；&#xD;
&#xD;
         20. Received any prescription drugs, over-the-counter (OTC) drugs, or Chinese herbal&#xD;
             medicines within 14 days prior to the first dose of study drug；&#xD;
&#xD;
         21. Received any nutritional supplies, including multivalent cations products (i.e. Ca-,&#xD;
             Al-, Mg-, Fe-, and Zn-containing products, nutritional supplements, multi-vitamin,&#xD;
             supplements for metals) within 7 days prior to the first dose of study drug；&#xD;
&#xD;
         22. History of alcohol misuse (14 units alcohol/ week: 1 unit equal to bear 285 mL,&#xD;
             spirits 25 mL, or wine 100 mL)；&#xD;
&#xD;
         23. Blood donation ≥400 ml within 3 months prior to the first dose of study drug；&#xD;
&#xD;
         24. Any disease or situation that would affect the safety of study drug or&#xD;
             pharmacokinetics profile by Investigators' judgments；&#xD;
&#xD;
         25. As determined by Investigator, a subject is not suitable to take part in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pingsheng Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>July 26, 2018</last_update_submitted>
  <last_update_submitted_qc>July 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy Chinese volunteers</keyword>
  <keyword>TG-2349</keyword>
  <keyword>DAG181</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>multiple ascending oral doses</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Yimitasvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

